1. Home
  2. LKFN vs PHVS Comparison

LKFN vs PHVS Comparison

Compare LKFN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakeland Financial Corporation

LKFN

Lakeland Financial Corporation

N/A

Current Price

$60.30

Market Cap

1.5B

Sector

Finance

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$24.23

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LKFN
PHVS
Founded
1872
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
LKFN
PHVS
Price
$60.30
$24.23
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$67.00
$39.44
AVG Volume (30 Days)
157.8K
534.0K
Earning Date
01-23-2026
11-12-2025
Dividend Yield
3.34%
N/A
EPS Growth
N/A
N/A
EPS
3.79
N/A
Revenue
$248,271,000.00
N/A
Revenue This Year
$17.16
N/A
Revenue Next Year
$3.98
N/A
P/E Ratio
$15.81
N/A
Revenue Growth
2.85
N/A
52 Week Low
$50.00
$11.51
52 Week High
$73.85
$29.80

Technical Indicators

Market Signals
Indicator
LKFN
PHVS
Relative Strength Index (RSI) 57.46 48.08
Support Level $59.00 $23.61
Resistance Level $60.56 $24.63
Average True Range (ATR) 1.33 1.94
MACD 0.27 -0.32
Stochastic Oscillator 87.73 16.47

Price Performance

Historical Comparison
LKFN
PHVS

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: